bluebird bio

The flock had an amazing time at Foundation for Sickle Cell Disease Research’s 18th Annual Sickle Cell Disease Research & Educational Symposium. Our birds were grateful for the opportunity to attend and hear from leaders and members of the #sicklecell community. As Shanna Gillis, Manager of Patient Advocacy, shared: “My first experience at FSCDR was phenomenal! The level of authentic engagement with the community and the thought-provoking educational opportunities were unmatched. I’m looking forward to bringing all my learnings back to the nest so the flock can continue to grow and improve.”

Last week, members of the flock migrated to #BIO2024. Here are some of the highlights of our team flying high: ➟ We shared perspective (and some hard-won lessons!) from a decade of gene therapy leadership during a fireside chat with Andrew Dunn from Endpoints News. ➟ We facilitated a conversation among pioneers from across the healthcare ecosystem who are blazing the trail for gene therapy access in the commercial setting. ➟ We took a training hike for Luke Timmerman's Timmerman Traverse with others from across the industry who are committed to paying it forward. ➟ We heard BIO International Convention’s new CEO John F. Crowley talk about his vision for the industry and the importance of keeping patients at the heart of our work, specifically sharing the New York Times piece highlighting sickle cell disease gene therapy. ➟ We connected with advocates and other innovators who are committed to changing the world for patients and families. ➟ We celebrated how far we’ve come and all that is ahead – for bluebird, for the field of gene therapy, and for patients and their families.

We asked some of the newest members of the bluebird bio flock: “Why do you fly?” Hear from members of the bPACE (bluebird Patient And Community Education) and my bluebird support flocks about why they are excited to educate and empower people living with severe genetic diseases. You may see them around at upcoming community events, so be sure to say hi and ask them more about why they fly! #SickleCellAwareness

Today, bluebird bio occupies a unique space as a standalone commercial gene therapy company. We are excited to share perspective from a decade of gene therapy leadership and continue learning from other pioneers in the field at #BIO2024. Come say hi if you’ll be in San Diego this week!

Living with beta-thalassemia is filled with many ups and downs, and the mental health impact of this journey is often overlooked. This #MentalHealthAwarenessMonth, remember that taking care of your mind is just as important as taking care of your body. By working together, we can continue raising awareness for mental health and #betathalassemia. 🧠💪#TakeAMentalBreak

As #MentalHealthAwarenessMonth comes to a close, we’re reflecting on the unique journeys we all face, especially when dealing with the burdens that can accompany living with sickle cell disease. For warriors and caregivers like Tiahna and TaLana, having the right support system can make all the difference in navigating the ups and downs. Thank you to advocates who shine light on this often stigmatized topic. 🧠💪 #SickleCellAwareness

While May marks AAPI Heritage Month, our flock remains committed to honoring the rich and diverse cultures of the AAPI community all year long. bUNITED, bluebird’s Employee Resource Group (ERG) dedicated to the Union for International Togetherness and Eastern Diversity, encourages you to engage in celebrating, learning about, and reflecting on the rich culture and histories of people of Asian, Native Hawaiian and Pacific Islander heritage in the US and across the world. 🌍❤️ #AAPIHeritageMonth

Today, bluebird bio reported first quarter 2024 results and business highlights, including the update that we have completed the first commercial cell collection for our sickle cell disease gene therapy. Learn more: https://lnkd.in/eF-i2xvt

Happy World Thalassemia Day! We’re grateful to the Cooley's Anemia Foundation for sharing their positive messages to the global #thalassemia community alongside bluebird’s Director of Patient Advocacy, Susan Brisendine, today.

#NewsFromTheNest: Today, bluebird bio announces the first person living with sickle cell has initiated treatment with our sickle cell disease gene therapy in the commercial setting.   Andrew Obenshain, chief executive officer, shares his reflection on this milestone: “Seeing people living with sickle cell disease receive gene therapy in the real world is a vision that has fueled bluebird for more than 10 years. This historic moment comes nearly a century after sickle cell disease was the first genetic disorder to be characterized at the molecular level, and almost a decade after bluebird initiated clinical development for our sickle cell gene therapy. We are grateful to the patients, caregivers, researchers, and clinicians whose work made this milestone possible, and look forward to continued partnership with the sickle cell disease community.”  Learn more: https://lnkd.in/e54XmAFP